

# Pr **DOJOLVI**<sup>®</sup>

## Triheptanoin Oral Liquid

BRITISH COLUMBIA

Ultragenyx Canada would like to announce that PrDOJOLVI<sup>®</sup> (triheptanoin) is covered for patients with LC-FAOD on a case-by-case basis through British Columbia's [Drugs for Rare Diseases \(EDRD\) process](#).

DOJOLVI<sup>®</sup> (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at [https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi\\_Final\\_PM.pdf](https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi_Final_PM.pdf) for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

For more information on applying for DOJOLVI<sup>®</sup> coverage, we can arrange an appointment at your convenience, or you can visit the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.